D.E. Shaw & Co
BMY.RT

D.E. Shaw & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

D.E. Shaw & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-667,318
Closed -$461K – 4695
2020
Q4 		$461K Sell
667,318
-8,400
-1% -$17.9K ﹤0.01% 3426
2020
Q3 		$1.52M Buy
675,718
+72,746
+12% +$208K ﹤0.01% 2577
2020
Q2 		$2.16M Sell
602,972
-1,921,460
-76% -$6.93M ﹤0.01% 2346
2020
Q1 		$9.59M Sell
2,524,432
-50,356
-2% -$166K 0.02% 1014
2019
Q4 		$7.75M Buy
+2,574,788
New +$6.7M 0.01% 1389

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

D.E. Shaw & Co's BMY.RT Position: Q1 2021 in Review

D.E. Shaw & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 667,318 shares — an estimated $461K sold.

D.E. Shaw & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $9.59M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • D.E. Shaw & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 667,318 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $461K.
  • D.E. Shaw & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • D.E. Shaw & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $9.59M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.